NIPRO CORPORATION Logo

NIPRO CORPORATION

Global manufacturer of renal care devices, injectable drugs, and pharmaceutical packaging.

8086 | T

Overview

Corporate Details

ISIN(s):
JP3673600007
LEI:
Country:
Japan
Address:
摂津市千里丘新町3番26号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Nipro Corporation is a global, comprehensive healthcare manufacturer founded in 1954. The company operates across four primary business segments: Medical Devices, Pharmaceuticals, Pharma Packaging, and Regenerative Medicine. Nipro is a market leader in renal care, providing a wide range of products for hemodialysis, including dialyzers and blood tubing. Its medical device portfolio also encompasses catheters, infusion kits, and blood collection tubes. The pharmaceuticals division specializes in the contract manufacturing of injectable drugs, while the pharma packaging business produces glass products such as vials and ampoules. Nipro focuses on developing unique technologies and products through its research and development sites to serve the needs of frontline medical treatment worldwide.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-21 02:30
Registration Form
発行登録書(株券、社債券等)
Japanese 29.3 KB
2025-11-14 02:30
Registration Form
確認書
Japanese 8.8 KB
2025-11-14 02:30
Interim / Quarterly Report
半期報告書-第73期(2025/04/01-2026/03/31)
Japanese 305.7 KB
2025-07-18 03:47
Prospectus
発行登録追補書類(株券、社債券等)
Japanese 125.7 KB
2025-07-03 03:01
Registration Form
訂正発行登録書
Japanese 9.7 KB
2025-07-03 03:00
AGM Information
臨時報告書
Japanese 36.5 KB
2025-06-27 02:50
Regulatory Filings
訂正発行登録書
Japanese 80.2 KB
2025-06-25 07:25
Governance Information
内部統制報告書-第72期(2024/04/01-2025/03/31)
Japanese 24.8 KB
2025-06-25 07:24
Registration Form
確認書
Japanese 8.7 KB
2025-06-25 07:24
Annual Report
有価証券報告書-第72期(2024/04/01-2025/03/31)
Japanese 1.8 MB
2025-03-25 07:31
Registration Form
訂正発行登録書
Japanese 9.7 KB
2025-03-25 07:30
Board/Management Information
臨時報告書
Japanese 23.8 KB
2025-03-21 07:31
Registration Form
訂正発行登録書
Japanese 9.7 KB
2025-03-21 07:30
Regulatory Filings
臨時報告書
Japanese 19.2 KB
2025-03-03 02:28
Regulatory Filings
訂正発行登録書
Japanese 9.8 KB

Automate Your Workflow. Get a real-time feed of all NIPRO CORPORATION filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NIPRO CORPORATION

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NIPRO CORPORATION via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Lineage Cell Therapeutics Inc. Logo
Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.
Israel
LCTX
Lipidor AB Logo
Develops topical skin treatments by reformulating drugs with a lipid-based delivery platform.
Sweden
LIPI
Lipocine Inc. Logo
Biopharma developing oral drugs for metabolic & endocrine disorders using delivery technology.
United States of America
LPCN
Liquidia Corp Logo
Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.
United States of America
LQDA
LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX

Talk to a Data Expert

Have a question? We'll get back to you promptly.